Shares of Advanced Biomed Inc. (ADVB) plunged another 17.6% to $8.96 on July 29, extending a brutal selloff that has now erased more than half the stock's value in just five trading days. The catalyst: the company's abrupt decision to cancel a planned securities offering, which initially sparked a speculative rally but has since triggered a violent unwind as traders rush for the exits. Advanced Biomed Lost More Than Half Its Value in Five Days — Can a Cash-Burning Micro-Cap Survive Without Fresh Capital?
Shares of Advanced Biomed Inc. (ADVB) cratered 17.6% to $8.96 on July 29, extending a five-day freefall that has wiped out roughly 53% of the stock's value since its July 24 peak of $18.98. The selloff is the hangover from a speculative rally that erupted when the company killed two separate capital-raising plans — and traders are now asking what a tiny biotech does when it slams the door on new money.
The Canceled Deals Sparked a Rally That Couldn't Last
Advanced Biomed terminated a purchase agreement that allowed up to $25 million in stock sales , effective July 21. Days earlier, the company also withdrew its Form S-1 registration statement, confirming that no securities were sold and none would be sold under it.
Investors initially cheered because canceling the offerings removed the threat of dilution — the risk that issuing new shares would shrink existing owners' stakes. ADVB surged as much as 77% in a single session. But that rally was built on momentum and short-term trading, not fundamentals, and the reversal has been just as violent.
The Company Is Burning Cash With No Revenue in Sight
ADVB's balance sheet shows minimal debt but the company is burning cash and posting sizable quarterly losses.
Net income declined 16% year-over-year and fell nearly 107% quarter-over-quarter. With no disclosed revenue and an estimated market cap of just ~$14.7 million, walking away from $25 million in potential funding raises a critical question: how does ADVB plan to finance its operations? The company did not disclose whether it plans to pursue an alternative capital-raising strategy.
A Shifting Identity Adds to the Uncertainty
A June 30 filing revealed ADVB agreed to sell its Taiwan subsidiary, which conducted its core biomedical research and development.
The rally also drew strength from the company's recent pivot away from life sciences and toward artificial intelligence — a dramatic reinvention that has yet to produce tangible results. Shedding the legacy business while chasing a new narrative without fresh capital is a high-wire act.
Speculative Volume Is Fading Fast
At its peak, 22 million ADVB shares traded in a single day — roughly 55 times the three-month average of about 400,000. That kind of volume signals speculative frenzy, not institutional conviction. In fact, three institutional investors exited their ADVB positions entirely in Q1 2026, and zero added shares. As momentum traders take profits and move on, the stock is left searching for a floor with no earnings, no clear strategy, and no fresh capital lined up.